Select Page

Genetic Editing Human Clinical Trials to Begin

CRISPR (i.e. clustered regularly interspaced short palindromic repeat), a segment of gene editing treatment that is thought to be one of the cutting edge developments in genetic engineering, is finally approaching clinical trials to be used on humans. Many are hopeful...

Internet Billionaire Sean Parker Behind First CRISPR Test

MIT Technology Review had some interesting news to break today: the first proposed test of CRISPR gene-editing technology in human beings is being funded by none other than Internet billionaire Sean Parker, the well-known cofounder behind Napster and first president...

Gene Editing Causing Challenges for EU Policymakers

After a quarter century of conflict over genetically modified foods, it’s understandable that initial reactions to gene editing—the technical process of editing or removing specific genes of an organism—being applied to produce and livestock have been met with...

Intellia Therapeutics Raises $108M in Upsized IPO

Novartis-backed, preclinical upstart Intellia Therapeutics ($NTLA) announced May 6th that it’s going for the top range of its IPO, selling 6 million shares at $18 a share to raise a total of $108 million. Founded in 2014, Intellia quickly caught the attention of...

U.K. Approves First Studies of CRISPR on Human Embryos

In my last blog post, I detailed the legal battle currently taking place over the biggest scientific breakthrough of 2015, a controversial gene edited technology called CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats.) On February 1st, the United...